Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patients.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
26 Jan 2024
26 Jan 2024
Historique:
received:
22
05
2023
accepted:
11
12
2023
medline:
27
1
2024
pubmed:
27
1
2024
entrez:
27
1
2024
Statut:
aheadofprint
Résumé
Primary cutaneous B-cell lymphomas (CBCL) are a group of rare malignant skin diseases that represent approximately 20%-30% of all primary cutaneous lymphomas (PCL). Previous studies revealed impaired health-related quality of life (HRQoL) in patients diagnosed with primary cutaneous T-cell lymphoma (CTCL). Currently, only small-sized studies investigated HRQoL in CBCL patients and lacked detailed analysis of respective subtypes. This study aims to investigate HRQoL in CBCL patients to identify independent factors of HRQoL impairment in CBCL patients. One hundred CBCL patients were recruited from eight German PCL centres in this multicentric, cross-sectional study from 2021 to 2022. The patients completed the dermatologic HRQoL questionnaire Skindex-29 and an investigator-designed 'CBCL-Questionnaire' with additional questions on HRQoL and clinical characteristics. The Skindex-29 revealed that HRQoL in CBCL patients is impaired on a mild to moderate level. The multiple regression analysis identified parameters like worries about dying, feeling prejudiced/discriminated and impairment of daily activities to be independently associated with impairment of HRQoL. Highest scores for HRQoL impairment were found in patients with primary cutaneous follicle centre lymphoma while on rituximab treatment and in patients with primary cutaneous marginal zone lymphoma while on watchful waiting. HRQoL is impaired in CBCL patients, even though, in the face of indolent disease course and favourable prognosis in the majority of cases. Of note, our investigator-designed tool identified worries about dying, feeling prejudiced/discriminated, and the type of treatment to have a negative impact on patients' HRQoL. Our study highlights the importance of a thorough patient-doctor communication to capture overall disease burden because generic HRQoL tools might lack of disease-specific items.
Sections du résumé
BACKGROUND
BACKGROUND
Primary cutaneous B-cell lymphomas (CBCL) are a group of rare malignant skin diseases that represent approximately 20%-30% of all primary cutaneous lymphomas (PCL). Previous studies revealed impaired health-related quality of life (HRQoL) in patients diagnosed with primary cutaneous T-cell lymphoma (CTCL). Currently, only small-sized studies investigated HRQoL in CBCL patients and lacked detailed analysis of respective subtypes.
OBJECTIVES
OBJECTIVE
This study aims to investigate HRQoL in CBCL patients to identify independent factors of HRQoL impairment in CBCL patients.
METHODS
METHODS
One hundred CBCL patients were recruited from eight German PCL centres in this multicentric, cross-sectional study from 2021 to 2022. The patients completed the dermatologic HRQoL questionnaire Skindex-29 and an investigator-designed 'CBCL-Questionnaire' with additional questions on HRQoL and clinical characteristics.
RESULTS
RESULTS
The Skindex-29 revealed that HRQoL in CBCL patients is impaired on a mild to moderate level. The multiple regression analysis identified parameters like worries about dying, feeling prejudiced/discriminated and impairment of daily activities to be independently associated with impairment of HRQoL. Highest scores for HRQoL impairment were found in patients with primary cutaneous follicle centre lymphoma while on rituximab treatment and in patients with primary cutaneous marginal zone lymphoma while on watchful waiting.
CONCLUSIONS
CONCLUSIONS
HRQoL is impaired in CBCL patients, even though, in the face of indolent disease course and favourable prognosis in the majority of cases. Of note, our investigator-designed tool identified worries about dying, feeling prejudiced/discriminated, and the type of treatment to have a negative impact on patients' HRQoL. Our study highlights the importance of a thorough patient-doctor communication to capture overall disease burden because generic HRQoL tools might lack of disease-specific items.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, et al. S2k-Leitlinie - Kutane Lymphome (ICD10 C82-C86): Update 2021. J Dtsch Dermatol Ges. 2022;20:537-555.
Nicolay JP, Wobser M. Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy. J Dtsch Dermatol Ges. 2016;14:1207-1224.
Wilcox RA. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2018;93:1427-1430.
Prinsen CA, de Korte J, Augustin M, Sampogna F, Salek SS, Basra MK, et al. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol. 2013;27:1195-1203.
Molloy K, Jonak C, Woei AJF, Guenova E, Busschots AM, Bervoets A, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2020;182:770-779.
Wright A, Wijeratne A, Hung T, Gao W, Whittaker S, Morris S, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manage. 2013;45:114-119.
Shalabi D, Kartan S, O'Donnell M, Zaya R, Zhan T, Shi W, et al. Skindex-29 scores indicate poor quality of life in early stage mycosis fungoides. J Dermatol Sci. 2020;98:98-101.
Semenov YR, Rosenberg AR, Herbosa C, Mehta-Shah N, Musiek AC. Health-related quality of life and economic implications of cutaneous T-cell lymphoma. Br J Dermatol. 2020;182:190-196.
Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, et al. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2021;184:722-730.
Holahan HM, Farah RS, Fitz S, Mott SL, Ferguson NN, McKillip J, et al. Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol. 2018;57:1314-1319.
Herbosa CM, Semenov YR, Rosenberg AR, Mehta-Shah N, Musiek AC. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology-specific instruments. J Eur Acad Dermatol Venereol. 2020;34:995-1003.
Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107:2504-2511.
Bhat TS, Herbosa CM, Rosenberg AR, Sogade O, Jeffe DB, Mehta-Shah N, et al. Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma. Br J Dermatol. 2021;184:310-318.
Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2021;35:2377-2387.
Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int. 2022;9:57-64.
Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Quality of life in cutaneous T-cell lymphoma patients receiving Mogamulizumab: important factors to consider. Cancers (Basel). 2022;15:15.
Beynon T, Selman L, Radcliffe E, Whittaker S, Child F, Orlowska D, et al. 'We had to change to single beds because I itch in the night': a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma. Br J Dermatol. 2015;173:83-92.
Beynon T, Radcliffe E, Child F, Orlowska D, Whittaker S, Lawson S, et al. What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence. Br J Dermatol. 2014;170:599-608.
Shinohara MM, Mahurin HM, Tarabadkar E, Hippe DS, Lachance K, Kim EJ, et al. Health-related quality of life in cutaneous T-cell lymphoma: a cross-sectional survey study. Skin Health Dis. 2021;1:e45.
Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, et al. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study. Eur J Cancer. 2020;133:120-130.
Dalal M, Mitchell S, McCloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. Expert Rev Hematol. 2020;13:405-419.
McCaffrey S, Black RA, Nagao M, Sepassi M, Sharma G, Thornton S, et al. Measurement of quality of life in patients with mycosis Fungoides/Sézary syndrome cutaneous T-cell lymphoma: development of an electronic instrument. J Med Internet Res. 2019;21:e11302.
Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol. 2021;192:683-696.
Sampogna F, Frontani M, Baliva G, Lombardo GA, Alvetreti G, Di Pietro C, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol. 2009;160:815-822.
Martinez XU, Chowdhury A, Stiller T, Palmer J, Loscalzo M, Barrios E, et al. The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas. Support Care Cancer. 2021;29:6669-6679.
Jonak C, Porkert S, Oerlemans S, Papadavid E, Molloy K, Lehner-Baumgartner E, et al. Health-related quality of life in cutaneous lymphomas: past, present and future. Acta Derm Venereol. 2019;99:640-646.
Porkert S, Lehner-Baumgartner E, Valencak J, Knobler R, Riedl E, Jonak C. Patients' illness perception as a tool to improve individual disease management in primary cutaneous lymphomas. Acta Derm Venereol. 2018;98:240-245.
Mapi Research Trust. Skindex. [cited 2023 Mar 24]. Available from: https://eprovide.mapi-trust.org/instruments/skindex
Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707-713.
Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433-1440.
Nijsten T, Sampogna F, Abeni D. Categorization of Skindex-29 scores using mixture analysis. Dermatology. 2009;218:151-154.
EORTC Quality of Life. Quality of life of cancer patients (QLQ-C30). [cited 2023 Mar 24]. Available from: https://qol.eortc.org/questionnaire/eortc-qlq-c30/
FACIT group. Functional Assessment of Cancer Therapy - General (FACT-G). [cited 2023 Mar 24]. Available from: https://www.facit.org/measures/FACT-G
Haraldstad K, Wahl A, Andenaes R, Andersen JR, Andersen MH, Beisland E, et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019;28:2641-2650.
Wenzel LB, Fairclough DL, Brady MJ, Cella D, Garrett KM, Kluhsman BC, et al. Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer. 1999;86:1768-1774.
Arndt V, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, Holleczek B, et al. Quality of life in long-term and very long-term cancer survivors versus population controls in Germany. Acta Oncol. 2017;56:190-197.
Hinz A, Schulte T, Ernst J, Mehnert-Theuerkauf A, Finck C, Wondie Y, et al. Sense of coherence, resilience, and habitual optimism in cancer patients. Int J Clin Health Psychol. 2023;23:100358.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, et al. Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. Hematol Oncol. 2021;39:658-663.
Hristov AC, Tejasvi T, Wilcox RA. Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1326-1332.
Falini B, Martino G, Lazzi S. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia. 2023;37:18-34.
Goodlad JR, Cerroni L, Swerdlow SH. Recent advances in cutaneous lymphoma-implications for current and future classifications. Virchows Arch. 2023;482:281-298.
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229-1253.
Mourad A, Gniadecki R. Overall survival in mycosis fungoides: a systematic review and meta-analysis. J Invest Dermatol. 2020;140:495-497.e5.
Eder J, Kammerstätter M, Erhart F, Mairhofer-Muri D, Trautinger F. Illness perception in primary cutaneous T-cell lymphomas: what patients believe about their disease. Acta Derm Venereol. 2016;96:381-385.
Major A, Wright R, Hlubocky FJ, Smith SM, Prochaska MT. Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance. Leuk Lymphoma. 2022;63:3331-3339.
Trevino KM, Martin P, Chen Z, Leonard JP. Worsening quality of life in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia patients in active surveillance: a 12-month longitudinal study. Clin Lymphoma Myeloma Leuk. 2022;22:82-88.
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424-435.
Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML, et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer. 2007;109:1659-1667.
Frey S, Blankart CR, Stargardt T. Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature. Pharmacoeconomics. 2016;34:479-498.
Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005;141:325-330.
Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, et al. Quality of life effect of the anti-CCR4 monoclonal antibody Mogamulizumab versus Vorinostat in patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21:97-105.
Molloy K, Jonak C, Pokert S, Lehner-Baumgartner E, Quaglino P, Borro A, et al. Update on the development of EORTC/CLTF questionnaires to assess HRQOL in primary cutaneous T-cell and B-cell lymphomas: phase I. Eur J Cancer. 2022;173:S19.